GLP-1 Healthcare is an independent resource for people considering, starting, or already taking a GLP-1 medication — and for the families helping them. We turn a confusing, fast-moving, and expensive topic into clear answers you can act on.
Why we exist
GLP-1 medications like semaglutide and tirzepatide have changed how obesity and type 2 diabetes are treated, but reliable, plain-language information about them is scattered across manufacturer marketing, competing telehealth brands, and forums. People deserve one place that explains costs, dosing, side effects, and how to find legitimate care — without an agenda to sell them a specific product.
What makes us different
- Independent. GLP-1 Healthcare is independently operated and is not owned by, affiliated with, or funded by any pharmaceutical manufacturer, telehealth prescriber, or pharmacy. See How We’re Funded.
- Sourced, not asserted. Every clinical claim is tied to a recognised authority. Browse the full source library.
- Honest about our limits. We tell you plainly what has and hasn’t been reviewed by a clinician, and we don’t invent expertise we don’t have.
Where we are today
We are an early-stage, independently operated publisher building toward becoming the definitive GLP-1 reference. We are actively recruiting credentialed medical reviewers — physicians, pharmacists, and registered dietitians — to review our clinical content. Until a page is reviewed by a named clinician, it says so. Our full standards are in our Editorial Policy.
Are you a qualified clinician?
We’re looking for board-certified physicians, pharmacists, and dietitians with experience in obesity medicine, endocrinology, or metabolic health to review content under their own name and credentials. If that’s you, we’d like to talk.
Important
GLP-1 Healthcare provides general educational information. It is not medical advice and is not a substitute for care from your own qualified healthcare provider. Never start, stop, or change a medication based solely on what you read here.